43O Durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm): Updated results from DUO-O

IF 7.1 2区医学 Q1 ONCOLOGY

ESMO Open Pub Date : 2024-06-01 DOI:10.1016/j.esmoop.2024.103550

F. Trillsch , A. Okamoto , J-W. Kim , A. Reuss , M.J. Rubio Pérez , M.A. Vardar , V. Salutari , J-S. Frenel , H. Kärkkäinen , N. Colombo , A.M. Chudecka-Glaz , P. Oppelt , S. Lheureux , C. Lamot , T. Engler , R.M. Wenham , S. Nishio , A. Correa , P. Harter , C. Aghajanian

引用次数: 0

查看原文本刊更多论文

43O Durvalumab（D）+卡铂/紫杉醇（CP）+贝伐珠单抗（B），然后D、B+奥拉帕利（O）维持治疗（mtx），用于治疗无肿瘤 BRCA1/BRCA2 突变（非 tBRCAm）的新诊断晚期卵巢癌（AOC）：DUO-O 的最新结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ESMO Open Medicine-Oncology

CiteScore

11.70

自引率

2.70%

发文量

255

审稿时长

10 weeks

期刊介绍： ESMO Open is the online-only, open access journal of the European Society for Medical Oncology (ESMO). It is a peer-reviewed publication dedicated to sharing high-quality medical research and educational materials from various fields of oncology. The journal specifically focuses on showcasing innovative clinical and translational cancer research. ESMO Open aims to publish a wide range of research articles covering all aspects of oncology, including experimental studies, translational research, diagnostic advancements, and therapeutic approaches. The content of the journal includes original research articles, insightful reviews, thought-provoking editorials, and correspondence. Moreover, the journal warmly welcomes the submission of phase I trials and meta-analyses. It also showcases reviews from significant ESMO conferences and meetings, as well as publishes important position statements on behalf of ESMO. Overall, ESMO Open offers a platform for scientists, clinicians, and researchers in the field of oncology to share their valuable insights and contribute to advancing the understanding and treatment of cancer. The journal serves as a source of up-to-date information and fosters collaboration within the oncology community.